Biology subjects

Harb, M.

Publications and source records attributed to Harb, M..

6 recordsLinked to original sources

bioRxiv2025

Site-Specific Noninvasive Delivery of Retrograde Viral Vectors to the Brain

Neuronal activity underlies the brain function. Different behaviors, physiological processes, and disorders depend on which neurons are active at a given moment. Treating brain disorders without side effects will require exclusive control of disease-relevant neurons. Traditionally, small molecule drugs could control a subset of neurons that express a molecularly specific receptor. Local noninvasive therapies such as delivery of neuromodulatory agents with focused ultrasound blood-brain barrier opening (FUS-BBBO) also added spatial precision allowing one to control specific brain regions without surgery. However, the final characteristic of neurons, which other neurons they connect to, remains underexplored as a therapeutic target. If targeting neurons based on their connectivity was possible noninvasively, it would open the doors to broadly deployable precise therapies that can target selected subgroups of neurons within a brain region. Such delivery could be achieved with retrograde-tracing adeno-associated viral vectors (AAVs). For noninvasive delivery with FUS-BBBO, AAV9 has emerged as the most promising serotype. However, its retrograde-tracing version, the AAV9.retro, has not been evaluated for FUS-BBBO delivery. Here, we show that following such noninvasive delivery AAV9.retro can safely transduce neuronal projections with comparable efficiency to a direct intracranial injection. Compared to AAV8, a naturally occurring vector with low retrograde transduction, AAV9.retro offers superior retrograde transduction and comparable transduction at the site of delivery. Overall, we show that AAV9.retro is a valuable FUS-BBBO gene delivery vector, while also highlighting the surprising possibility of improved specificity of transduction of projections compared to invasive delivery.

bioengineering↗

bioRxiv2024

Monitoring in vivo transcription with synthetic serum markers

Understanding transcription profiles of living tissues is critical for biology and medicine. However, measurement of the transcript levels is typically done in homogenized tissues post-mortem. Here, we present a new platform that enables non-invasive monitoring of specific mRNA levels in vivo, without tissue destruction. We achieved this by combining two cutting-edge tools - synthetic serum markers, called Released Markers of Activity (RMAs), and RNA-based sensors of transcription. We call this platform IN-vivo Tracking of ACtive Transcription, or INTACT. In INTACT, when the target mRNA is expressed, the RNA sensor detects it and triggers the production and release of RMA reporters into the blood. Once in blood, the RMAs can be easily measured through a simple blood draw. Our data shows that INTACT can measure transcription of transgenes, as well as endogenous transcripts, such as c-Fos or Arc, both in vivo in the brain and in tissue culture. INTACT enables simple measurement of transcript level histories in genetically-targetable cell populations of living animals.

bioengineering↗

bioRxiv2023

Engineering Regionally-Activated Drugs for Neuroscience

The brain is comprised of multiple regions performing distinct functions. Within each of these regions, there are multiple cell types that can affect brain physiology. Finally, within each cell there are multiple signaling pathways, that, when activated or inhibited, control the cells activity, and consequently the brain function. For these reasons, methods that can control the brain with regional, cell-type, and molecular precision have been widely used in neuroscience. However, so far, achieving sustained control over a brain region with that level of specificity relied either on gene delivery or placement of invasive devices. While gene therapy holds great promise, the risks of genomic integration, vector toxicity, vector-directed immune response, high cost, and gene delivery to the brain pose significant challenges. On the other hand, invasive devices enable site-specific delivery of drugs but can also surgically damage the modulated brain region, carrying risks of infection and hemorrhage. Here, we present a new approach that can provide multi-day, noninvasive, site-specific control over specific cell types in the brain without the need to use invasive devices or gene delivery. To achieve this, we introduce a new paradigm called Regionally Activated Interstitial Drugs, or RAID, which delivers a protein-based catalytic centers, or RAID enzymes, to the brain using focused ultrasound blood-brain barrier opening. This catalytic center is designed to attach to the interstitial space in the brain where it remains for days after initial delivery. While the catalytic center is present in the brain, it can locally process an inert BBB permeable prodrug into an active drug, resulting in localized therapy. Our proof-of concept studies demonstrated that the engineered RAID enzymes can retain activity in the brain parenchyma for several days, allowing for noninvasive site-specific induction of neuronal activity that was sufficiently potent to elicit behavioral effects. Overall, the RAID paradigm enabled noninvasive, tunable, temporally-re-solved, site-specific, non-genetic, neuromodulation over multiple days. The RAID paradigm is versatile and can be applied to any enzyme and prodrug pair to control various aspects of central nervous system physiology.

bioengineering↗

bioRxiv2020

Induction of Ventral Spinal V0 Interneurons from Mouse Embryonic Stem Cells

The ventral spinal population of V0 interneurons (INs) contribute to the coordinated movements directed by spinal central pattern generators (CPGs), including respiratory circuits and left-right alternation. One challenge in studying V0 INs has been the limited number of cells that can be isolated from primary sources for basic research or therapeutic use. However, derivation from a pluripotent source, such as has been done recently for other IN populations could reduce this issue. However, there is currently no protocol to specifically derive V0 interneurons from embryonic stem cells or induced pluripotent stem cells. To generate an induction protocol, mouse embryonic stem cells (mESCs) were grown in suspension culture and then exposed to retinoic acid (RA) and collected at different time points to measure mRNA expression of the V0 progenitor transcription factor marker, Dbx1, and post-mitotic transcription factor marker, Evx1. The cultures were also exposed to the sonic hedgehog signaling pathway agonist purmorphamine (purm) and the Notch signaling pathway inhibitor N-{N-(3,5-difluorophenacetyl-L-alanyl)}-(S)-phenylglycine-t-butyl-ester (DAPT) to determine if either of these pathways contribute to V0 IN induction, specifically the ventral (V0V) subpopulation. From the various parameters tested, the final protocol that generated the greatest percentage of cells expressing V0V IN markers was an 8 day protocol using 4 days of suspension culture to form embryoid bodies followed by addition of 1 M RA from days 4 to 8, 100 nM purm from days 4 to 6, and 5 M DAPT from days 6 to 8. This protocol will allow investigators to obtain V0 IN cultures for use in in vitro studies, such as those examining CPG microcircuits, electrophysiological characterization, or even for transplantation studies in injury or disease models.

developmental biology↗

bioRxiv2020

Candida albicans exhibits distinct cytoprotective responses to anti-fungal drugs that facilitate the evolution of drug resistance

We developed a modified protocol for nanolitre droplet-based single cell sequencing appropriate for fungal settings, and used it to transcriptionally profiled several thousands cells from a prototrophic Candida albicans population and several drug exposed colonies (incl. fluconazole, caspofungin and nystatin). Thousands of cells from each colony were profiled both at early and late time points post-treatment in order to infer survival trajectories from initial drug tolerance to drug resistance. We find that prototrophic C. albicans populations differentially and stochastically express cytoprotective epigenetic programs. For all drugs, there is evidence that tolerant individuals partition into distinct subpopulations, each with a unique survival strategy involving different regulatory programs. These responses are weakly related to changes in morphology (shift from white to opaque forms, or shift from yeast to filamentous forms). In turn, those subpopulations that successfully reach resistance each have a distinct multivariate epigenetic response that coordinates the expression of efflux pumps, chaperones, transport mechanisms, and cell wall maintenance. Live cell fluorescent imaging was used to validate predictions of which molecular responses most often led to survival after drug exposure. Together our findings provide evidence that C. albicans has a robust toolkit of short-term epigenetic cytoprotective responses designed to "buy time" and increase the chance of acquiring long-term resistance.

genomics↗

bioRxiv2019

Comparative analysis of intracellular and extracellular antibiotic resistance gene abundance in anaerobic membrane bioreactor effluent

The growing practice of wastewater reuse poses a significant risk to further dissemination of antibiotic resistance due to the abundance of antibiotic resistance bacteria (ARB) and antibiotic resistance genes (ARGs) in wastewater effluents. Anaerobic membrane bioreactors (AnMBRs) are an emerging wastewater treatment technology capable of reducing the total ARGs and ARB load discharged to receiving environments compared to conventional aerobic treatment processes. While size exclusion is effective at retaining ARB and its associated intracellular ARGs, the abundance and fate of extracellular ARGs in an AnMBR effluent have not been examined. This study elucidates the effect of combined antibiotics loading (ampicillin, erythromycin, and sulfamethoxazole) on the abundance of intracellular and extracellular ARGs in an AnMBR effluent over a period of five weeks. Quantification of targeted genes revealed an overall enrichment of intracellular ARGs (iARGs) and depletion of extracellular (exARGs) in response to antibiotics addition, which suggests exARG uptake as a significant mode of horizontal gene transfer in AnMBR effluents. Comparison of the iARG and exARG abundance profiles showed a potential bias for exARG uptake located on small plasmids compared to large plasmids.\n\nImportanceAntibiotic resistance dissemination is facilitated through horizontal gene transfer (HGT) of ARGs. Currently, conjugation is considered to be the dominant mechanism during wastewater treatment. However, recent studies have detected high abundances of exARGs, implying that transformation may play a greater role in dissemination. While previous studies quantified iARGs and exARGs in wastewater treatment facilities, they did not evaluate temporal changes between the two forms. Further, almost no research has differentiated between iARGs and exARGs in anaerobic processes, which are being considered to replace aerobic activated sludge processes. This study specifically investigates the abundance of targeted iARGs and exARGs in AnMBRs in response to antibiotic pressure to quantify potential exchange of ARGs between intracellular and extracellular compartments. Our findings suggest that exARGs located on small plasmids are preferentially taken up by cells under antibiotic pressure compared to large plasmids, which implies heterogenous HGT mechanisms among the plasmid community.

ecology↗